Corxel Pharmaceuticals closed a $287 million Series D to advance its oral GLP‑1 receptor agonist CX‑11 through pivotal development and expand global trials. The financing will support U.S. Phase II readouts, planned Phase III preparations, and broader cardiometabolic programs. Investors signaled strong market appetite for oral obesity therapies, mirroring ongoing capital flows into GLP‑1 modalities. Corxel’s pill is framed as a differentiated, potentially injectable‑competitive option and the round underscores continuing investor enthusiasm for obesity/metabolic drug development.